FDA 483 - Boston Scientific Corporation - September 22, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspection of Boston Scientific Corporation in Saint Paul, MN, revealed significant non-compliance with Good Laboratory Practice (GLP) regulations during nonclinical laboratory studies, particularly study 13-137G. Key issues included deviations from study protocols, inaccuracies in final reports, inadequate quality assurance oversight, and failures in data integrity, personnel qualifications, and record archiving. These observations highlight systemic deficiencies in the firm's preclinical device evaluation processes.
ID · b22eaf57-c029-4d9c-a52d-a096f55fe00f